These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 26807550)

  • 1. Sabril® registry 5-year results: Characteristics of adult patients treated with vigabatrin.
    Krauss G; Faught E; Foroozan R; Pellock JM; Sergott RC; Shields WD; Ziemann A; Dribinsky Y; Lee D; Torri S; Othman F; Isojarvi J
    Epilepsy Behav; 2016 Mar; 56():15-9. PubMed ID: 26807550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Which children receive vigabatrin? Characteristics of pediatric patients enrolled in the mandatory FDA registry.
    Pellock JM; Faught E; Foroozan R; Sergott RC; Shields WD; Ziemann A; Lee D; Dribinsky Y; Torri S; Othman F; Isojarvi J
    Epilepsy Behav; 2016 Jul; 60():174-180. PubMed ID: 27208827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Registry initiated to characterize vision loss associated with vigabatrin therapy.
    Pellock JM; Faught E; Sergott RC; Shields WD; Burkhart GA; Krauss GL; Foroozan R; Wesche DL; Weinberg MA
    Epilepsy Behav; 2011 Dec; 22(4):710-7. PubMed ID: 21978471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A lack of clinically apparent vision loss among patients treated with vigabatrin with infantile spasms: The UCLA experience.
    Schwarz MD; Li M; Tsao J; Zhou R; Wu YW; Sankar R; Wu JY; Hussain SA
    Epilepsy Behav; 2016 Apr; 57(Pt A):29-33. PubMed ID: 26921595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primer on visual field testing, electroretinography, and other visual assessments for patients treated with vigabatrin.
    Sergott RC; Westall CA
    Acta Neurol Scand Suppl; 2011; (192):48-56. PubMed ID: 22061180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding and interpreting vision safety issues with vigabatrin therapy.
    Plant GT; Sergott RC
    Acta Neurol Scand Suppl; 2011; (192):57-71. PubMed ID: 22061181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Balancing clinical benefits of vigabatrin with its associated risk of vision loss.
    Pellock JM
    Acta Neurol Scand Suppl; 2011; (192):83-91. PubMed ID: 22061183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval.
    Tolman JA; Faulkner MA
    Expert Opin Pharmacother; 2009 Dec; 10(18):3077-89. PubMed ID: 19954276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retinal structure and function in vigabatrin-treated adult patients with refractory complex partial seizures.
    Sergott RC; Johnson CA; Laxer KD; Wechsler RT; Cherny K; Whittle J; Feng G; Lee D; Isojarvi J
    Epilepsia; 2016 Oct; 57(10):1634-1642. PubMed ID: 27580566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vigabatrin: 2008 update.
    Willmore LJ; Abelson MB; Ben-Menachem E; Pellock JM; Shields WD
    Epilepsia; 2009 Feb; 50(2):163-73. PubMed ID: 19230067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ACS chemical neuroscience molecule spotlight on Sabril.
    Hopkins CR
    ACS Chem Neurosci; 2010 Jul; 1(7):475. PubMed ID: 22778839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of vigabatrin in childhood seizure disorders: results from a clinical audit.
    Prasad AN; Penney S; Buckley DJ
    Epilepsia; 2001 Jan; 42(1):54-61. PubMed ID: 11207785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Visual field loss in patients with refractory partial epilepsy treated with vigabatrin: final results from an open-label, observational, multicentre study.
    Wild JM; Chiron C; Ahn H; Baulac M; Bursztyn J; Gandolfo E; Goldberg I; Goñi FJ; Mercier F; Nordmann JP; Safran AB; Schiefer U; Perucca E
    CNS Drugs; 2009 Nov; 23(11):965-82. PubMed ID: 19845417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of visual field loss following exposure to vigabatrin therapy: a systematic review.
    Maguire MJ; Hemming K; Wild JM; Hutton JL; Marson AG
    Epilepsia; 2010 Dec; 51(12):2423-31. PubMed ID: 21070215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Visual field constriction on vigabatrin.
    Prescrire Int; 2000 Feb; 9(45):210-1. PubMed ID: 11503799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Visual function is stable in patients who continue long-term vigabatrin therapy: implications for clinical decision making.
    Paul SR; Krauss GL; Miller NR; Medura MT; Miller TA; Johnson MA
    Epilepsia; 2001 Apr; 42(4):525-30. PubMed ID: 11440348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Epilepsy and Sabril].
    Depasse F
    Bull Soc Belge Ophtalmol; 2007; (304):33-40. PubMed ID: 17718226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vigabatrin.
    Wheless JW; Ramsay RE; Collins SD
    Neurotherapeutics; 2007 Jan; 4(1):163-72. PubMed ID: 17199033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vigabatrin for infantile spasms.
    Pesaturo KA; Spooner LM; Belliveau P
    Pharmacotherapy; 2011 Mar; 31(3):298-311. PubMed ID: 21361740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A risk-benefit assessment of treatments for infantile spasms.
    Nabbout R
    Drug Saf; 2001; 24(11):813-28. PubMed ID: 11665869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.